BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 33392502)

  • 1. Preclinical and first-in-human-brain-cancer applications of [
    Young RJ; Demétrio De Souza França P; Pirovano G; Piotrowski AF; Nicklin PJ; Riedl CC; Schwartz J; Bale TA; Donabedian PL; Kossatz S; Burnazi EM; Roberts S; Lyashchenko SK; Miller AM; Moss NS; Fiasconaro M; Zhang Z; Mauguen A; Reiner T; Dunphy MP
    Neurooncol Adv; 2020; 2(1):vdaa119. PubMed ID: 33392502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluorine-18 labeled poly (ADP-ribose) polymerase1 inhibitor as a potential alternative to 2-deoxy-2-[
    Demétrio de Souza França P; Roberts S; Kossatz S; Guru N; Mason C; Zanoni DK; Abrahão M; Schöder H; Ganly I; Patel SG; Reiner T
    Nucl Med Biol; 2020; 84-85():80-87. PubMed ID: 32135475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioiodinated PARP1 tracers for glioblastoma imaging.
    Salinas B; Irwin CP; Kossatz S; Bolaender A; Chiosis G; Pillarsetty N; Weber WA; Reiner T
    EJNMMI Res; 2015 Dec; 5(1):123. PubMed ID: 26337803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
    Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
    J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Feasibility of PARP1/2 Imaging with
    Schöder H; França PDS; Nakajima R; Burnazi E; Roberts S; Brand C; Grkovski M; Mauguen A; Dunphy MP; Ghossein RA; Lyashchenko SK; Lewis JS; O'Donoghue JA; Ganly I; Patel SG; Lee NY; Reiner T
    Clin Cancer Res; 2020 Jul; 26(13):3110-3116. PubMed ID: 32245901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma.
    Carlucci G; Carney B; Brand C; Kossatz S; Irwin CP; Carlin SD; Keliher EJ; Weber W; Reiner T
    Mol Imaging Biol; 2015 Dec; 17(6):848-55. PubMed ID: 25895168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP1-targeted fluorescence molecular endoscopy as novel tool for early detection of esophageal dysplasia and adenocarcinoma.
    Marcazzan S; Braz Carvalho MJ; Nguyen NT; Strangmann J; Slotta-Huspenina J; Tenditnaya A; Tschurtschenthaler M; Rieder J; Proaño-Vasco A; Ntziachristos V; Steiger K; Gorpas D; Quante M; Kossatz S
    J Exp Clin Cancer Res; 2024 Feb; 43(1):53. PubMed ID: 38383387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discriminating radiation injury from recurrent tumor with [
    Donabedian PL; Kossatz S; Engelbach JA; Jannetti SA; Carney B; Young RJ; Weber WA; Garbow JR; Reiner T
    EJNMMI Res; 2018 Jul; 8(1):59. PubMed ID: 29974335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.
    Carney B; Carlucci G; Salinas B; Di Gialleonardo V; Kossatz S; Vansteene A; Longo VA; Bolaender A; Chiosis G; Keshari KR; Weber WA; Reiner T
    Mol Imaging Biol; 2016 Jun; 18(3):386-92. PubMed ID: 26493053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo visualization of PARP inhibitor pharmacodynamics.
    McDonald ES; Pantel AR; Shah PD; Farwell MD; Clark AS; Doot RK; Pryma DA; Carlin SD
    JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted
    Young AJ; Pantel AR; Viswanath V; Dominguez TL; Makvandi M; Lee H; Li S; Schubert EK; Pryma DA; Farwell MD; Mach RH; Simpkins F; Lin LL; Mankoff DA; Doot RK
    J Nucl Med; 2022 Jan; 63(1):44-50. PubMed ID: 33863820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study of a PARP1-targeted topical fluorophore for the detection of oral cancer.
    Demétrio de Souza França P; Kossatz S; Brand C; Karassawa Zanoni D; Roberts S; Guru N; Adilbay D; Mauguen A; Valero Mayor C; Weber WA; Schöder H; Ghossein RA; Ganly I; Patel SG; Reiner T
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3618-3630. PubMed ID: 33954826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy.
    Nguyen NT; Pacelli A; Nader M; Kossatz S
    Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
    Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
    Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and Delineation of Oral Cancer With a PARP1-Targeted Optical Imaging Agent.
    Kossatz S; Weber W; Reiner T
    Mol Imaging; 2017; 16():1536012117723786. PubMed ID: 28856922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polyethylene Glycol 3350 (PEG 3350) as a Practical Vehicle for Rapid Reconstitution of PARPi-FL Formulations for Clinical Use.
    Demétrio de Souza França P; Viray T; Roberts S; Michel A; Abrahão M; Patel SG; Ganly I; Schöder H; Brand C; Reiner T; Pillarsetty NVK
    Mol Imaging Biol; 2023 Apr; 25(2):294-302. PubMed ID: 35882728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
    Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two experts and a newbie: [
    Stotz S; Kinzler J; Nies AT; Schwab M; Maurer A
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):834-846. PubMed ID: 34486071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
    Rajawat J; Shukla N; Mishra DP
    Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.